Artiva Biotherapeutics (ARTV) Current Assets (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Current Assets for 4 consecutive years, with $88.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets fell 47.8% year-over-year to $88.7 million; the TTM figure through Mar 2026 stood at $88.7 million (down 47.8% YoY), while the FY2025 annual figure was $112.7 million, down 40.27% from the prior year.
• Current Assets fell to $88.7 million in Q1 2026 per ARTV's latest filing, from $112.7 million in the prior quarter.
• Across five years, Current Assets topped out at $188.6 million in Q4 2024 and bottomed at $49.7 million in Q2 2024.
• Historically, Current Assets has averaged $124.3 million across 4 years, with a median of $129.5 million in 2025.
• Annual changes were most pronounced in 2025 — Current Assets jumped 199.64% — and 2026, when it tumbled 47.8%.
• Artiva Biotherapeutics' Current Assets stood at $79.8 million in 2023, then soared by 136.32% to $188.6 million in 2024, then plunged by 40.27% to $112.7 million in 2025, then declined by 21.24% to $88.7 million in 2026.
• Business Quant data shows ARTV's Current Assets at $88.7 million in Q1 2026, $112.7 million in Q4 2025, and $129.5 million in Q3 2025.